Revolutionizing Cancer Research: Invivoscribe and Complete Genomics Team Up to Introduce Innovative Biomarker Tests!

Today, Invivoscribe and Complete Genomics announced a comprehensive partnership to transform oncology and cancer research around the world. The two companies have combined forces to develop and market advanced biomarker testing utilizing Complete Genomics’ cutting-edge next-generation sequencing (NGS) platforms. With this collaboration, researchers are poised to unlock powerful insights into the genomic landscape of cancer.

Invivoscribe has partnered with a new biotechnology company to develop a set of innovative biomarker tests that will revolutionize the way we measure MRD in a clinical setting. These tests will be initially released worldwide as Research Use Only; in the long-term, they will be validated and utilised to support commercialization of in vitro diagnostic testing products as well as clinical studies and regulatory submissions around the world. With the potential to revolutionize MRD detection, this partnership promises to be groundbreaking.

We are delighted to collaborate with Complete Genomics in order to bring their groundbreaking Next Generation Sequencing (NGS) platforms to our customers. With Complete Genomics’ lower cost systems and reagents compared to other NGS providers, it has become easier to access our LeukoStrat® CDx FLT3 Mutation Assay – an internationally standardized, FDA and IVDR approved PCR-based capillary test – which is so powerful as a companion diagnostic for three approved FLT3 targeted therapies.

Our FLT3-ITD MRD test, which is currently offered as a CLIA/CAP testing service in our LabPMM laboratories, is going to be developed as a RUO kit on the Complete Genomics DNBSEQ-G99 platform, making it easier for researchers to track and monitor AML disease levels and residual disease in AML patients.

“We are thrilled to be partnering with Invivoscribe, a proven developer of high-quality tests to deliver a complete workflow solution,” Yongwei Zhang, CEO of Complete Genomics.

The Complete Genomics DNBSEQ-G99 platform is pioneering groundbreaking tests for the screening and highly sensitive monitoring of an array of hematologic malignancies, especially Acute Myeloid Leukemia (AML). A particularly sinister form of blood cancer, AML is known for its devastating mortality rate, with only 31.7% of patients surviving 5 years after diagnosis.

Even worse, about 25% of those afflicted with AML also carry a FLT3-ITD mutation, an oncogenic factor associated with a poor prognosis. Advancing research on this platform will hopefully bring a glimmer of hope for AML patients.

About Invivoscribe

Invivoscribe is a global, vertically-integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics®. For nearly thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized reagents, tests, bioinformatics tools, and services to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with global pharmaceutical companies, providing expertise in diagnostic development and regulatory submission through commercialization of companion diagnostics.

About Complete Genomics

Since 2005, Complete Genomics has been a leader in the life sciences field, providing innovative end to end DNA sequencing solutions that have propelled over 4,000 publications in a variety of applications. We are at the forefront of high throughput sequencing technology development and continue to strive for more progress in this rapidly evolving space. Our products have the potential to drastically change the future of medical research and healthcare.

Leave a Comment